- Home
- BIOA vs ABUS Comparison
BIOA vs ABUS Comparison
Compare BIOA & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIOA | ABUS |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | 64 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 856.3M | 884.7M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | BIOA | ABUS |
|---|---|---|
| Price | $21.13 | $4.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $51.80 | $5.00 |
| AVG Volume (30 Days) | 448.5K | ★ 2.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,171,000.00 |
| Revenue This Year | N/A | $125.30 |
| Revenue Next Year | $898.47 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.88 | $2.71 |
| 52 Week High | $24.00 | $5.10 |
Technical Indicators
Market Signals| Indicator | BIOA | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 55.10 | 47.67 |
| Support Level | $18.62 | $4.23 |
| Resistance Level | $22.25 | $4.76 |
| Average True Range (ATR) | 1.42 | 0.23 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 67.45 | 26.56 |
Price Performance
Historical ComparisonAbout BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.